A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2011
10/18/2011	US8039487 Piperidine-amide derivatives
10/18/2011	US8039464 Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
10/18/2011	CA2484038C Estrogen receptor modulators
10/18/2011	CA2480438C Novel use of the extract of processed ginseng and saponin isolated therefrom
10/18/2011	CA2478813C Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/18/2011	CA2475312C N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
10/18/2011	CA2470643C Cleavable reagents for specific delivery to disease sites
10/18/2011	CA2466906C Pharmaceutical composition comprising a prostaglandin e1
10/18/2011	CA2440644C Inhibitors of integrin .alpha.v.beta.6
10/18/2011	CA2337328C Biocompatible polymers, preparation method and compositions containing same
10/13/2011	WO2011127393A2 Variants of ancestral uricases and uses thereof
10/13/2011	WO2011127300A1 Crystalline forms of prasugrel salts
10/13/2011	WO2011127090A1 Conditioned medium obtained form stem cells and its use in therapy
10/13/2011	WO2011126264A2 Method for increasing activity in human stem cell
10/13/2011	WO2011124638A1 Pimobendan manufacturing process
10/13/2011	WO2011124430A1 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
10/13/2011	WO2011123942A1 Fatty acid derivatives of catechins and methods of their use
10/13/2011	WO2011079343A3 Substituted pyridines and pyrimidines for the production of cardiomyocyte - like cells
10/13/2011	WO2011062864A3 Inhibitors of nox enzymes and methods of use thereof
10/13/2011	WO2011057249A3 Treatment of heart disease
10/13/2011	WO2011047040A3 Methods and compositions to support transplanted tissue integration and innosculation with adipose stromal cells
10/13/2011	WO2011038086A3 Indolizine inhibitors of 5-lipoxygenase
10/13/2011	US20110251677 Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings
10/13/2011	US20110251288 Process for the preparation of enantiomerically pure amines
10/13/2011	US20110251276 Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease
10/13/2011	US20110251275 Omega-3 fatty acids for reduction of lp-pla2 levels
10/13/2011	US20110251274 Natural Vitamin E Compositions with Superior Antioxidant Potency
10/13/2011	US20110251260 NOVEL siRNAS AND METHODS OF USE THEREOF
10/13/2011	US20110251256 Use of trim72 as a target for muscle and heart enhancer
10/13/2011	US20110251249 Dual-acting antihypertensive agents
10/13/2011	US20110251245 Solid pharmaceutical composition comprising amlodipine and losartan
10/13/2011	US20110251238 Ppar agonist compositions and methods of use
10/13/2011	US20110251226 Cyclohexylamin isoquinolone derivatives
10/13/2011	US20110251224 Spiro-oxindole compounds and their uses as therapeutic agents
10/13/2011	US20110251220 Pharmaceutical compositions comprising gamma secretase modulators
10/13/2011	US20110251218 Novel compounds
10/13/2011	US20110251217 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
10/13/2011	US20110251212 Piperazine derivatives
10/13/2011	US20110251211 Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
10/13/2011	US20110251208 Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
10/13/2011	US20110251207 Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
10/13/2011	US20110251203 Use of pkc inhibitors in diabetic complications
10/13/2011	US20110251200 Aryl guanidine f1f0-atpase inhibitors and related methods
10/13/2011	US20110251197 Lysosomotropic inhibitors of acid ceramidase
10/13/2011	US20110251185 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
10/13/2011	US20110251183 Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
10/13/2011	US20110251182 Agents and methods for treating ischemic and other diseases
10/13/2011	US20110251180 Pharmaceutical agent comprising quinolone compound
10/13/2011	US20110251176 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
10/13/2011	US20110251175 Stigmine Conjugates for Substance Use Disorders
10/13/2011	US20110251171 Heterocyclic compounds and methods of use
10/13/2011	US20110251168 3-aminopyrrolidine derivatives as modulators of chemokine receptors
10/13/2011	US20110251166 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptor
10/13/2011	US20110251165 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptor
10/13/2011	US20110251160 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
10/13/2011	US20110251158 Fullerene therapies for inflammation and inhibition of build-up of arterial plaque
10/13/2011	US20110251128 THYMOSIN Beta4 PEPTIDES PROMOTE TISSUE REGENERATION
10/13/2011	US20110251122 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
10/13/2011	US20110250703 Il1rl-1 as a cardiovascular disease marker and therapeutic target
10/13/2011	US20110250300 Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
10/13/2011	US20110250299 Organogel compositions and processes for producing
10/13/2011	US20110250297 Treatment of Hyperproliferative Disorders Using Cardiac Glycosides
10/13/2011	US20110250296 Reverse vitamin k effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
10/13/2011	US20110250279 Controlled-release composition for producing sustained-release preparation containing udenafil
10/13/2011	US20110250272 Solid, orodispersible and/or dispersible composition, without an excipient of known effect and its process of preparation
10/13/2011	US20110250261 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
10/13/2011	US20110250243 Nanoparticle compositions
10/13/2011	US20110250240 Immune enhancing compositions and methods of use thereof
10/13/2011	US20110250219 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
10/13/2011	US20110250215 Structurally-related relaxin-fusion proteins with extended in vivo half-lives
10/13/2011	US20110250210 Neutralizing Antibodies and Fragments Thereof Directed Against Platelet Factor-4 Variant 1 (PF4V1)
10/13/2011	US20110250208 Oxidized Cardiolipin as a Novel Pro-Inflammatory Factor
10/13/2011	US20110250206 Markers for determination of patient responsiveness
10/13/2011	US20110250201 Antagonists of il-6 to raise albumin and/or lower crp
10/13/2011	US20110250197 Pharmaceutical combination
10/13/2011	US20110250193 Composition comprising expression or activity inhibitors of ninjurin1 for the prevention and treatment of inflammatory disease
10/13/2011	US20110250190 Pharmaceutical preparation
10/13/2011	US20110250183 Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction
10/13/2011	US20110250182 Angiogenesis using placental stem cells
10/13/2011	US20110250180 Ccn3 peptides and analogs thereof for therapeutic use
10/13/2011	US20110250169 Derivatives of growth hormone and related proteins
10/13/2011	US20110250142 Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
10/13/2011	US20110250134 Sustained release nitric oxide from long lived circulating nanoparticles
10/13/2011	DE102010014411A1 New iron complexes, useful as carbon monoxide and iron releasing molecules for treating e.g. high blood pressure, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis, sepsis, angina and myocardial infarction
10/13/2011	CA2795750A1 Modulation of cetp expression
10/13/2011	CA2795518A1 Angiogenesis using placental stem cells
10/13/2011	CA2788762A1 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
10/12/2011	EP2374876A2 Therapy for alpha-galactosidase a deficiency
10/12/2011	EP2374819A1 Antibodies to MASP-2
10/12/2011	EP2374798A1 Benzazepine derivatives useful as vasopressin antagonists
10/12/2011	EP2374797A1 Benzazepine derivatives useful as vasopressin antagonists
10/12/2011	EP2374796A1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders
10/12/2011	EP2374508A1 Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia
10/12/2011	EP2374458A1 Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS
10/12/2011	EP2374457A1 Antihypertensive pharmaceutical composition
10/12/2011	EP2374456A1 Activated blood coagulation factor x (fxa) inhibitor
10/12/2011	EP2374454A1 Hemiasterlin derivatives and uses thereof in the treatment of cancer
10/12/2011	EP2374453A1 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
10/12/2011	EP2374452A1 Nutrient composition
10/12/2011	EP2373645A1 Isoindolinone and related analogs as sirtuin modulators

1 ... 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 ... 1595